PepJunkie Home of the Peptonauts
More

Peptide Atlas · Other substance

Thymostimulin (TP-1)

In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improved clinical scores at three months, but the difference did not last and immunological measures did not change.

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

No protocol has enough distinct humans behind it to be a protocol. One person saying it twice is still one person.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.